Board of Directors

Marty Tenenbaum, PhD
Founder & Chairman of the Board
Cancer Commons

Marty Tenenbaum, PhD
Founder & Chairman of the Board
Cancer Commons

Marty Tenenbaum is a renowned computer scientist, Internet entrepreneur and cancer survivor. He founded Cancer Commons and CollabRx (NASD: CRLX) to help each cancer patient obtain the best possible outcome. He is an Internet commerce pioneer and visionary, having founded EIT (1990) and CommerceNet (1994) to accelerate business use of the Internet, and later, was an officer and director of Commerce One, Webify Solutions (sold to IBM in 2006),  and Medstory (sold to Microsoft in 2007). He currently serves on the boards of Efficient Finance, Patients Like Me, and the Public Library of Science (PLoS).

Dr. Tenenbaum is a fellow and former board member of the Association for the Advancement of Artificial Intelligence (AAAI), and a former consulting professor of Computer Science at Stanford. He holds B.S. and M.S. degrees in Electrical Engineering and Computer Science from MIT, and a Ph.D. from Stanford.

Laurence J. Marton, MD
Member of the Board of Trustees
American Association for Cancer Research Foundation

Laurence J. Marton, MD
Member of the Board of Trustees
American Association for Cancer Research Foundation

Dr. Marton serves as a consultant to industry and to nonprofit, government, and academic institutions. In the nonprofit sector, Dr. Marton serves on the Board of Trustees of the American Association for Cancer Research Foundation and on the Board of Directors of Cancer Commons.

In the for-profit sector, he serves on the Board of Directors of Cellsonics, Dategra, Matternet, Microsonic Systems, Nanotics, Omniox (also serving as Executive Chair), RenovoRx, and xCures; is Chair of the Scientific Advisory Board of PharmaJet; is an advisor to Assurance Health Data, Ciitizen, Enable Medicine, Immunai, and the Precision Medicine World Conference; and is on the Editorial Board of the Journal of Precision Medicine.

Previously, Dr. Marton was Dean of the University of Wisconsin Medical School and Chaired the Department of Laboratory Medicine at UCSF, where he was a Professor in the Departments of Laboratory Medicine and Neurological Surgery. Dr. Marton received his MD from the Albert Einstein College of Medicine.

Gladys H. Monroy, PhD, JD
Senior Partner
Morrison Foerster

Gladys H. Monroy, PhD, JD
Senior Partner
Morrison Foerster

Dr. Gladys H. Monroy has specialized in intellectual property strategy in the field of Life Sciences since 1986.  Her practice has included structuring and maintaining complex patent portfolios for companies ranging in size from start-up to large corporations, patent litigation, trade secret litigation, freedom of operation opinions and validity opinions, due diligence analysis of intellectual property portfolios for mergers, acquisitions, and financing including IPOs.

Dr. Monroy joined Morrison & Foerster LLP (MoFo) as a partner in 1990.  She was a founder of the Patent Law Group at the firm and was Chair of the Patent Group from 1997 to 2006.  She retired from her position of Senior Partner in 2015.

Dr. Monroy has served as the President of the Silicon Valley Intellectual Property Law Association, and on the Board of the Intellectual Property Committee of the CA State Bar.  She has received recognition and many awards for her legal work.  These include:

  • The Patent Hall of Fame
  • Best Lawyers in America
  • Who’s Who in Law
  • Top Rating in Chambers USA
  • Chambers USA Women in Law Award: Intellectual Property Lawyer of the Year (2012)

Dr. Monroy received her B.A. in Chemistry from Hunter College, an M.S. in Biology from N.Y.U., and a Ph.D. in Biochemistry from N.Y.U. Medical School.  She was a Post-Doctoral Fellow in Molecular Biology and Cancer at Albert Einstein School of Medicine, and an Assistant Professor of Microbiology at N.Y. Medical College.  She was also a Research Associate at U.C.S.F.  Dr. Monroy received her J.D. from U.S.F.

Dr. Monroy’s Bar Admissions include:

  • State Bar of California
  • United States Patent and Trademark Office
  • Court of Appeals of the Federal Circuit
  • United States Supreme Court

Dr. Monroy serves on several non-profit Boards.  She is on the Board of Cancer Commons, and is a Trustee of the American Association for Cancer Research.  Her work with the Weizmann Institute of Science includes the following: she is Regional Co-chair of the Bay Area for the American Committee for the Weizmann Institute (ACWIS), is a member of the Executive Committee of ACWIS, is a member of the International Board of the Weizmann Institute, and has been chosen to be the President of ACWIS in 2020.

Edgar D. Staren, MD, PhD, MBA
Former CEO
Cancer Treatment Centers of America (CTCA)

Edgar D. Staren, MD, PhD, MBA
Former CEO
Cancer Treatment Centers of America (CTCA)

Edgar D. Staren, MD, PhD, MBA, has previously served as CEO of CTCA Medicine and Science. He is President of TransMed7, LLC and President of its subsidiary, Martinet Medical, LLC, minimal access medical technology companies addressing patient needs from diagnosis to therapy. Most recently he served as Professor of Surgery, Vice President and Executive Director for Cancer Services at Wake Forest University Baptist Medical Center, and Deputy Director for Clinical Affairs of its Comprehensive Cancer Center. He is a graduate of Loyola University School of Medicine and received his general surgery training and surgical oncology fellowship at Rush University Medical Center and Cook County Hospitals. Additional graduate education included a PhD in immunology/microbiology from Rush and an MBA from Benedictine University.

After his training, Dr. Staren remained as a faculty member at Rush and held positions as Professor of General Surgery and Associate Dean for Medical Student Programs. He subsequently served as Professor and Chairman of Surgery at the Medical College of Ohio and Medical Director of the MCO Cancer Institute, CEO of CTCA Medicine and Science, as well as, CEO of Ashion PMed Management, an outgrowth of the Translational Genomics Research Institute (TGen).

Dr. Staren is a member of numerous academic organizations and has published nearly 300 scientific works including more than 150 manuscripts, 80+ abstracts, 45 book chapters, and 12 books.

Vern Norviel
Partner
Wilson Sonsini Goodrich & Rosati

Vern Norviel
Partner
Wilson Sonsini Goodrich & Rosati

Vern Norviel is a partner at Wilson Sonsini Goodrich & Rosati, where he leads the patents and innovations counseling practice. Vern has three decades of experience in formulating successful strategies for life science companies and the development of their IP programs. He represents a wide variety of companies, as well as venture capital firms, in areas such as therapeutics, diagnostics, nanotechnology, genomics, proteomics, and personalized medicine. In fact, Vern’s interest in the field of personalized medicine prompted him to become the first attorney to have had his or her entire genome sequenced and made available in a public database. Before joining the firm in 2003, Vern was the general counsel and corporate secretary of Perlegen Sciences, Inc., a start-up biotechnology company that scans the entire human genome for important therapeutic and diagnostic products. Previously, as senior vice president and general counsel, he was an early employee of Affymetrix, the biotechnology company that pioneered and developed DNA chip technology. He also had been a partner at Townsend and Townsend and Crew in Palo Alto. During his career, Vern has authored or prosecuted more than 20 patents that have been litigated in the United States and abroad, and has overseen intellectual property lawsuits throughout the world. Vern previously served as a member of Wilson Sonsini Goodrich & Rosati’s board of directors and currently serves on the board of the WSGR Foundation. In addition, he is a lecturer in biotechnology law at UC Berkeley School of Law.

Mark Jacobstein
Chief Business Officer
Immunai

Mark Jacobstein
Chief Business Officer
Immunai

Mark Jacobstein is the Chief Business Officer for Immunai, a high growth startup using single cell genomics and machine learning to reprogram the immune system. Mark came to Immunai by way of Guardant Health, where he spent four years as the Chief User Engagement Officer. Prior to this Mark was CEO of mobile VOIP-provider iSkoot until its acquisition by Qualcomm. Mark was also an EVP at loopt (sold to GreenDot) and the co-founding President of Sequoia-backed Digital Chocolate, a pioneer in mobile games.

In 1994 Mark founded Small World Sports, the world’s first online fantasy sports business, and served as CEO until he sold the business to Paul Allen in 2002. Mark also co-founded Small World Software, which he sold to iXL, where he served as SVP of business development through their 1998 IPO.  

Mark earned his BA from Harvard, where he concentrated in Computer Science, and lives in Stanford, CA with his wife and daughter.

David D. Daly
President and COO
Singular Genomics

David D. Daly
President and COO
Singular Genomics

Dave has almost 30 years of executive leadership in prominent scientific companies, including startups and large-scale commercial organizations. Dave is currently President and COO of Singular Genomics, a next generation multiomics molecular technology company, leveraging a unique sequencing technology to open up new frontiers in oncology, immune profiling, single cell, spatial, and proteomics. 

Prior to Singular, Dave was the CEO at Thrive Earlier Detection where he grew the business and oversaw a $2.15 billion acquisition in January 2021. Prior to Thrive, he was at Illumina as the senior vice president and general manager of commercial operations for the Americas region. In this capacity, he played a key role in the company’s long-range planning process and helped to accelerate adoption of the company’s flagship NovaSeq sequencing platform.

Previously, Dave was general manager and chief commercial officer at Foundation Medicine, where he was responsible for all commercial functions, including sales, marketing, client services, payer relations, and medical affairs. Dave was also the oncology business unit leader at Life Technologies, served as Chief Commercial Officer at Clarient, and worked with other health care firms like Roche Diagnostics and Abbott Laboratories.

Paul Billings, M.D., Ph.D.
Chief Medical Officer
Natera Inc.

Paul Billings, M.D., Ph.D.
Chief Medical Officer
Natera Inc.

Dr. Paul R. Billings is a board-certified internist and clinical geneticist, who also holds a PhD in Immunology, from Harvard University.  He worked there with Dr. Baruj Benacerraf, who subsequently received the Nobel Prize in Medicine. 

In 2018, Dr. Billings became the Chief Medical Officer and Senior Vice President for Medical Affairs at Natera, Inc., a global leader in human genetic testing.  Dr Billings recently has been a Partner in the diagnostic medicine consultancy, the Bethesda Group, and the Managing Director of the Bethesda Group Fund.  

He is Chairman of PlumCare, LLC and Synergenz Biosciences Limited.  He has held academic and research appointments at Harvard University, UC San Francisco, Stanford University and UC Berkeley.  He has published approximately 200 papers and volumes.  He co-founded the stem cell company, CBR Systems, was a Director at Ancestry.com and Signature Genomics Inc, and is co-founder and senior advisor of Fabric Genomics, Inc., a leading genome informatics firm.

Since June of 2019 he is also Chairman of the Board of OmniSeq, Inc, a cancer diagnostic company affiliated with Roswell Park Cancer Center in Buffalo, NY. He is also a Director at OmniSeq Inc., which provides novel cancer and immunodiagnostic testing.  Dr.  Billings advises or directs several other firms in the precision medicine field. 

Until 2018, Dr. Billings was the Chairman of Biological Dynamics, a revolutionary molecular measurement platform.  Dr. Billings was the SVP and Senior Physician at Laboratory Corporation of America, Inc. and Chief Medical Officer at Life Technologies Inc,(Applied Biosystems) and later the clinical division of ThermoFisher Scientific Inc.  He is an expert in precision medicine diagnostics particularly in Oncology, Transplantation and Women’s Health.